The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database
Open accessAbstract
OBJECTIVE: To examine the risk of non-fatal idiopathic venous thromboembolism in current users of a combined oral contraceptive containing drospirenone, relative to current users of preparations containing levonorgestrel. DESIGN: Nested case-control study. SETTING: UK General Practice Research Database. PARTICIPANTS: Women aged 15-44 years without major risk factors for venous thromboembolism who started a new episode of use of an oral contraceptive containing 30 µg oestrogen in combination with either drospirenone or levonorgestrel between May 2002 and September 2009. Cases were women with a first diagnosis of venous thromboembolism; up to four controls, matched by age, duration of recorded information, and general practice, were randomly selected for each case. MAIN OUTCOME MEASURES: Odds ratios and 95% confidence intervals estimated with conditional logistic regression; age adjusted incidence rate ratio estimated with Poisson regression. RESULTS: 61 cases of idiopathic venous thromboembolism and 215 matched controls were identified. In the case-control analysis, current use of the drospirenone contraceptive was associated with a threefold higher risk of non-fatal idiopathic venous thromboembolism compared with levonorgestrel use; the odds ratio adjusted for body mass index was 3.3 (95% confidence interval 1.4 to 7.6). Subanalyses suggested that referral, diagnostic, first time user, duration of use, and switching biases were unlikely explanations for this finding. The crude incidence rate was 23.0 (95% confidence interval 13.4 to 36.9) per 100,000 woman years in current users of drospirenone and 9.1 (6.6 to 12.2) per 100,000 woman years in current users of levonorgestrel oral contraceptives. The age adjusted incidence rate ratio was 2.7 (1.5 to 4.7). CONCLUSIONS: These findings contribute to emerging evidence that the combined oral contraceptive containing drospirenone carries a higher risk of venous thromboembolism than do formulations containing levonorgestrel.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sterne, J. A. C., White, I. R., Carlin, J. B., Spratt, M., Royston, P., Kenward, M. G., Wood, A. M., & Carpenter, J. R. (2009) · BMJ · doi:10.1136/bmj.b2393 · Cited by 7,299
Multiple imputation of discrete and continuous data by fully conditional specification
van Buuren, S. (2007) · Statistical Methods in Medical Research · doi:10.1177/0962280206074463 · Cited by 2,827
Hormonal contraception and risk of venous thromboembolism: national follow-up study
Lidegaard, O., Lokkegaard, E., Svendsen, A. L., & Agger, C. (2009) · BMJ · doi:10.1136/bmj.b2890 · Cited by 709
Cited by
Lidegaard, O., Nielsen, L. H., Skovlund, C. W., Skjeldestad, F. E., & Lokkegaard, E. (2011) · BMJ · doi:10.1136/bmj.d6423 · Cited by 608
Thrombotic stroke and myocardial infarction with hormonal contraception
Lidegaard, Ø., Løkkegaard, E., Jensen, A., Skovlund, C. W., & Keiding, N. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1111840 · Cited by 607
Escobar-Morreale, H. F., Carmina, E., Dewailly, D., Gambineri, A., Kelestimur, F., Moghetti, P., Pugeat, M., Qiao, J., Wijeyaratne, C. N., Witchel, S. F., et al. (2012) · Human Reproduction Update · doi:10.1093/humupd/dmr042 · Cited by 494
Stanczyk, F. Z., Hapgood, J. P., Winer, S., & Mishell, D. R. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1008 · Cited by 429
Stegeman, B. H., de Bastos, M., Rosendaal, F. R., van Hylckama Vlieg, A., Helmerhorst, F. M., Stijnen, T., & Dekkers, O. M. (2013) · BMJ · doi:10.1136/bmj.f5298 · Cited by 420
Combined oral contraceptives: venous thrombosis
de Bastos, M., Stegeman, B. H., Rosendaal, F. R., Van Hylckama Vlieg, A., Helmerhorst, F. M., Stijnen, T., & Dekkers, O. M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010813.pub2 · Cited by 399
Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10
Lidegaard, O., Nielsen, L. H., Skovlund, C. W., & Lokkegaard, E. (2012) · BMJ · doi:10.1136/bmj.e2990 · Cited by 326
Dragoman, M. V., Tepper, N. K., Fu, R., Curtis, K. M., Chou, R., & Gaffield, M. E. (2018) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.12455 · Cited by 253
Gronich, N., Lavi, I., & Rennert, G. (2011) · Canadian Medical Association Journal · doi:10.1503/cmaj.110463 · Cited by 135
Horton, L. G., Simmons, K. B., & Curtis, K. M. (2016) · Contraception · doi:10.1016/j.contraception.2016.05.014 · Cited by 75
Hirsutism: an evidence-based treatment update
Somani, N., & Turvy, D. (2014) · American Journal of Clinical Dermatology · doi:10.1007/s40257-014-0078-4 · Cited by 69
Shah, D., Patil, M., & On behalf of the National PCOS Working Group (2018) · Journal of Human Reproductive Sciences · doi:10.4103/jhrs.jhrs_72_18 · Cited by 51
Pharmacodynamics of combined estrogen-progestin oral contraceptives: Effects on metabolism
Bastianelli, C., Farris, M., Rosato, E., Brosens, I., & Benagiano, G. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1271708 · Cited by 50
Bird, S. T., Delaney, J. A. C., Etminan, M., Brophy, J. M., & Hartzema, A. G. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12224 · Cited by 22
Estrogen and thrombosis: controversies and common sense
DeLoughery, T. G. (2011) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-011-9178-0 · Cited by 21
Metadata
- Authors
- Parkin, L., Sharples, K., Hernandez, R. K., & Jick, S. S.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2011-04-21
- Volume
- 342
- Issue
- apr21 2
- Pages
- d2139-d2139
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2037699368
- Cited by
- 203
- References
- 3
- FWCI
- 30.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.